期刊文献+

卵巢癌靶向基因治疗研究进展 被引量:1

下载PDF
导出
摘要 卵巢癌死亡率居女性生殖系统恶性肿瘤之首,基因治疗是治疗卵巢癌的一种新手段。卵巢癌的靶向基因治疗能提高对肿瘤细胞的杀伤作用而不影响正常细胞,是目前研究的热点。载体是基因治疗的关键。目前应用的载体系统主要分为两大类:病毒载体和非病毒载体。利用卵巢癌的特殊启动子和靶向基因可以提高基因治疗的靶向性。卵巢癌靶向基因治疗的方法主要有:分子化疗、RNA干扰、免疫基因治疗、多药耐药基因治疗和联合基因治疗。卵巢癌的靶向基因治疗目前尚处于临床前实验阶段。
作者 伍霞 钟玲
出处 《国际妇产科学杂志》 CAS 2008年第3期190-193,共4页 Journal of International Obstetrics and Gynecology
  • 相关文献

参考文献20

  • 1[1]Itamochi H,Kigawa J,Kanamori Y,et al.Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma:a potential treatment strategy[J].Mol Cancer Ther,2007,6(1):227-235.
  • 2[2]Lam JT,Kanerva A,Bauerschmitz GJ,et al.Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy[J].J Gene Med,2004,6(12):1333-1342.
  • 3[3]Page JG,Tian B,Schweikart K,et al.Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus,Ad5-delta24-RGD,in anticipation of a phase I trial for recurrent ovarian cancer[J].Am J Obstet Gynecol,2007,196(4):3891-3899.
  • 4[4]Caracciolo G,Pozzi D,Caminiti R,et al.Structural characterization of a new lipid/DNA complex showing a selective transfection efficiency in ovarian cancer cells[J].Eur Phys J E Soft Matter,2003,10(4):331-336.
  • 5[5]Rein D T,Breidenbach M,Kirby To,et al.A fiber-modified,secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer[J].Clin Cancer Res,2005,11(3):1327-1335.
  • 6[6]Zhu ZB,Makhija SK,Lu B,et al.Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter[J].Gene Ther 2004,11(7):645-648.
  • 7[7]Rocconi RP,Zhu ZB,Stoff-Khalili M,et al.Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd)[J].Gynecol Oncol,2007,105(1):113-121.
  • 8[8]Goodell V,Salazar LG,Urban N,et al.Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer[J].J Clin Oncol,2006,24(5):762-768.
  • 9[9]Collinet P,Vereecque R,Sabban F,et al.In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice[J].J Obstet Gynaecol Res,2006,32(5):449-453.
  • 10[10]Le Page C,Ouellet V,Madore J,et al.Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer[J].Br J Cancer,2006,94(3):436-445.

同被引文献19

  • 1汤军桥,葛海良.卵巢癌基因治疗的研究现状及进展[J].国外医学(妇产科学分册),2006,33(4):259-263. 被引量:2
  • 2陈煜,谢小芳.RNAi的作用机制及抗病毒研究进展[J].世界华人消化杂志,2006,14(21):2123-2129. 被引量:11
  • 3席勇,邓燕杰.卵巢癌基因治疗研究与进展[J].国外医学(妇产科学分册),2007,34(3):196-199. 被引量:3
  • 4Kramm CM,Niehues T,Rainov NG.Experimental strategies for combined suicide and immune cancer gene therapy[J].Methods Mol Biol,2003,215(6):137-152.
  • 5Caracciolo G,Pozzi D,Caminiti R,et al.Structural characterization of a new lipid /DNA complex showing a selective transfection efficiency in ovarian cancer cells[J].Eur Phys J E Soft Matter,2003,10(4):331-336.
  • 6Dachs GU,Tupper J,Tozer GM.From bench to bedside for gene directed enzyme prodrug therapy of cancer[J].Anticancer Drugs,2005,16(4):349-359.
  • 7Ziller C,Lincet H,Muller CD,et al.The cyclin-dependent kinase inhibitor p21cipl /waf1 enhances the cytotoxicity of gancielovir in HSV-tk transfected ovarian carcinoma cells[J].Cancer Lett,2004,212(1):43-52.
  • 8Song Y,Kong B,Ma D,et al.Procaspase-3 enhances the in vitro effect cytosine deam inase-thymidine kinase disuicide gene therapy on human ovarian cancer[J].Int J Gynecol Cancer,2006,16(1):156-164.
  • 9Hamstra DA,Lee KC,Tychewicz JM,et al.The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies[J].Mol Ther,2004,10(5):916-928.
  • 10Noske A,Kaszubiak A,Weichert W,et al.Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation:increased expression of AKT in advanced ovarian cancer[J].Cancer Lett,2007,246(1-2):190-200.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部